Showing 31 - 40 of 467
We study the effects of a change in the way patient reimbursements are calculated on the prices of pharmaceuticals using quasi-experimental data for Denmark which switched from external (where reimbursements are based on prices of similar products in foreign countries) to internal reference...
Persistent link: https://www.econbiz.de/10011122563
Reference price systems for prescription drugs constitute widely adopted cost containment tools. Under these regimes, patients co-pay a fraction of the difference between a drug's pharmacy retail price and a reference price that is set by the government. Reference prices are either externally...
Persistent link: https://www.econbiz.de/10011051273
On April 1, 2005, Denmark changed the way references prices, a main determinant of reimbursements for pharmaceutical purchases, are calculated. The previous reference prices, which were based on average EU prices, were substituted to minimum domestic prices. Novel to the literature, we estimate...
Persistent link: https://www.econbiz.de/10008534454
On April 1, 2005, Denmark changed the way references prices, a main determinant of reimbursements for pharmaceutical purchases, are calculated. The previous reference prices, which were based on average EU prices, were substituted to minimum domestic prices. Novel to the literature, we estimate...
Persistent link: https://www.econbiz.de/10008694123
Persistent link: https://www.econbiz.de/10001508561
Persistent link: https://www.econbiz.de/10001533646
Persistent link: https://www.econbiz.de/10001438245
Persistent link: https://www.econbiz.de/10001581887
Persistent link: https://www.econbiz.de/10001689554
Persistent link: https://www.econbiz.de/10001701737